Kanaph Therapeutics to Participate in "BIO USA 2026" ... Business Development Discussions
"Focused on Achieving Tangible Business Development Outcomes"
Kanaph Therapeutics, a company specializing in the development of innovative bispecific antibodies and antibody-drug conjugates (ADCs) based on the human genome, announced on June 16 that it will participate in "BIO USA 2026," the world’s largest biotechnology event, to be held in San Diego, USA, from June 22 to 25 (local time).
According to data recently released by Kanaph Therapeutics at major conferences such as AACR and ARVO, KNP-301 has demonstrated VEGF (vascular endothelial growth factor) inhibitory activity comparable to standard therapies for wet age-related macular degeneration, as well as competitive complement inhibition efficacy compared to standard therapies for geographic atrophy. KNP-101 has shown the potential to minimize systemic toxicity while maintaining intratumoral antitumor immune activity even in repeated dosing environments.
Based on these research achievements, the company has received partnering meeting requests from more than 20 global pharmaceutical and biotech companies at BIO USA. CEO Byungchul Lee and Head of Business Development Youngsoo Yoon will directly engage in business development discussions. As global pharmaceutical companies are showing increasing interest in KNP-301 and other key pipelines, Kanaph Therapeutics plans to further advance ongoing discussions as well as accelerate the search for new strategic partnerships.
Hot Picks Today
"We'll Pay 100% of Bonuses in Stock, Not Cash"...Employees Voting at This Company
- "Losing Jobs and Selling Bean Sprouts: Why They Left a Job Earning 6.76 Million Won per Month"
- "How Much Further Can It Fall?" Balances Fluctuate as KOSPI Drops 5% After Two Days of Gains
- Cardiac Arrests Surge in 40-Degree Heatwave, Hospitals Overwhelmed... Paris Issues Emergency "No Drinking" Ban
- "‘Hong Myungbo Banned from Entry’ Posted on Convenience Store Door... Headquarters Investigating Store Location"
A representative from Kanaph Therapeutics stated, "BIO USA is an important event for discussing concrete business collaboration plans with potential partners,” adding, “With growing global interest in our diverse pipeline, we are focused on achieving tangible business development outcomes through this event.”
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
